Elian V et al
It is also required in the conversion of vitamin B6 to its active form, and in the conversion of tryptophan to niacin (vitamin B3)
Document their understanding and any questions
Traditionally, the Ashwagandha root is used, however new research has found high concentrations of key components in the leaves too
HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1263 PFIZER INC.: COMPANY OVERVIEW TABLE 1264 PFIZER INC.: PRODUCTS OFFERED TABLE 1265 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1266 PFIZER INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 1267 MERCK & CO., INC.: COMPANY OVERVIEW TABLE 1268 MERCK & CO., INC.: PRODUCTS OFFERED TABLE 1269 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1270 MERCK & CO., INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 1271 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1272 NOVARTIS AG: COMPANY OVERVIEW TABLE 1273 NOVARTIS AG: PRODUCTS OFFERED TABLE 1274 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1275 NOVARTIS AG: DEALS, JANUARY 2022APRIL 2025 TABLE 1276 NOVARTIS AG: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1277 BAYER AG: COMPANY OVERVIEW TABLE 1278 BAYER AG: PRODUCTS OFFERED TABLE 1279 BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1280 BAYER AG: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1281 ASTRAZENECA: COMPANY OVERVIEW TABLE 1282 ASTRAZENECA: PRODUCTS OFFERED TABLE 1283 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1284 ASTRAZENECA: DEALS, JANUARY 2022APRIL 2025 TABLE 1285 ASTRAZENECA: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1286 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW TABLE 1287 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED TABLE 1288 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1289 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2022APRIL 2025 TABLE 1290 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1291 ELI LILLY AND COMPANY: COMPANY OVERVIEW TABLE 1292 ELI LILLY AND COMPANY: PRODUCTS OFFERED TABLE 1293 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1294 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1295 AMGEN INC.: COMPANY OVERVIEW TABLE 1296 AMGEN INC.: PRODUCTS OFFERED TABLE 1297 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1298 AMGEN INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 1299 AMGEN INC.: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1300 NOVO NORDISK A/S: COMPANY OVERVIEW TABLE 1301 NOVO NORDISK A/S: PRODUCTS OFFERED TABLE 1302 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1303 NOVO NORDISK A/S: DEALS, JANUARY 2022APRIL 2025 TABLE 1304 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022APRIL 2025 TABLE 1305 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW TABLE 1306 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED TABLE 1307 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1308 REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022APRIL 2025 TABLE 1309 FRESENIUS KABI AG: COMPANY OVERVIEW TABLE 1310 FRESENIUS KABI AG: PRODUCTS OFFERED TABLE 1311 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1312 UCB S.A.: COMPANY OVERVIEW TABLE 1313 UCB S.A.: PRODUCTS OFFERED TABLE 1314 UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1315 BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW TABLE 1316 BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED TABLE 1317 BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022APRIL 2025 TABLE 1318 SAGENT: COMPANY OVERVIEW TABLE 1319 VALNEVA SE: COMPANY OVERVIEW TABLE 1320 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW TABLE 1321 PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW TABLE 1322 HERON THERAPEUTICS, INC.: COMPANY OVERVIEW FIGURE 1 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION FIGURE 2 INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION FIGURE 3 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS FIGURE 8 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH FIGURE 9 TOP-DOWN APPROACH FIGURE 10 BOTTOM-UP APPROACH FIGURE 11 DATA TRIANGULATION METHODOLOGY FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS
